Transcriptional activation of microRNA-34a by NF-kappa B in human esophageal cancer cells by Li, Juan et al.
RESEARCH ARTICLE Open Access
Transcriptional activation of microRNA-34a by
NF-kappa B in human esophageal cancer cells
Juan Li, Kai Wang, Xuedan Chen, Hui Meng, Min Song, Yan Wang, Xueqing Xu
* and Yun Bai
*
Abstract
Background: miR-34a functions as an important tumor suppressor during the process of carcinogenesis. However,
the mechanism of miR-34a dysregulation in human malignancies has not been well elucidated. Our study aimed to
further investigate the regulation mechanism of miR-34a.
Results: We found that overexpression of NF-kappa B p65 subunit could increase miR-34a levels in EC109, an
esophageal squamous cancer cell line, while ectopic expression of DN IkappaB leaded to a significant reduction of
miR-34a expression. Bioinformatics analysis suggested three putative KB sites in promoter region of miR-34a gene.
Mutation two of these KB sites impaired p65 induced miR-34a transcriptional activity. Chromatin
immunoprecipitation and electrophoretic mobility shift assays both showed that NF-kappaB could specifically bind
to the third KB site located in miR-34a promoter. In addition, we found that overexpression of NF-kappaB p65
could not successfully induce miR-34a expression in esophageal cancer cell lines with mutant p53 or decreased
p53. Reporter assay further showed that NF-kappaB-induced miR-34a transcriptional activity was reduced by p53
impairment. Nevertheless, CHIP analysis suggested binding of NF-kappaB to miR-34a promoter was not affected in
cells with mutant p53.
Conclusions: Our work indicates a novel mechanism of miR-34a regulation that NF-kappaB could elevate miR-34a
expression levels through directly binding to its promoter. And wildtype p53 is responsible for NF-kappaB-
mediated miR-34a transcriptional activity but not for NF-kappaB binding. These findings might be helpful in
understanding miR-34a abnormality in human malignancies and open new perspectives for the roles of miR-34a
and NF-kappaB in tumor progression.
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Background
MicroRNAs (miRNAs) are small, non-coding RNAs that
negatively regulate gene expression at the posttranscrip-
tional level. Emerging evidence has demonstrated that
these small RNAs are involvedi na l m o s te v e r ya s p e c t s
of tumor biology and could function as oncogenes or
tumor suppressor genes [1]. MiR-34a has recently been
found to act as an important tumor suppressor in the
development of various cancers. A variety of genes
referring to cell cycle and apoptosis control, such as
CDK4/6, cyclin D1, E2F3, MYCN, and SIRT1and Bcl2
are demonstrated to be downregulated by miR-34a
[2-11]. MiR-34a could also inhibit cell migration and
invasion through targeting c-Met [12]. Recent data sug-
gest that dysregulation of miR-34a exists in many types
of human cancers and is correlated with clinic treatment
[13-17]. Although the most important regulator of miR-
34a expression is the well-known tumor suppressor p53
[7-10], p53 abnormality is not always correlated with
low levels of miR-34a in human cancer tissues. In
chronic lymphocytic leukemia, deletion or mutation of
p53 is associated with miR-34a downregulation [14-16].
While in neuroblastoma and non-small-cell lung cancer,
no significant correlation between p53 mutation and
miR-34a dysregulation is observed [17]. Though
researchers have reported other mechanisms for miR-
34a abnormality, like deletion of 1p36.3, aberrant CpG
methylation or CEBPa mutation [13,17-19], more
detailed study on regulation of miR-34a transcription is
of great importance.
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existed transcription factor regulating expression of
numerous genes involving in inflammation, immune and
cancer progression [20]. In an inactive status, NF-B
family members exist as dimmers with the predomi-
nance of p65/p50 heterodimers and are sequestered in
the cytoplasm by members of IB family. When NF-B
pathway is activated by a series of stimuli, IBp r o t e i n s
are phosphorylated and degraded in a proteasome
dependent manner leading to nuclear translocation of
NF-B and activation of downstream gene expression
[21]. Although numerous studies suggest that activation
of NF-B signal lead to resistance to apoptosis, incon-
trollable cell proliferation, metastasis, and angiogenesis
[20], there are also evidence indicating a tumor-suppres-
sor like effect of NF-B. Different research groups have
independently reported that blockade of NF-Bs i g n a l
pathway caused a significant increase in spontaneous
epithelial squamous cell carcinoma or diethylnitrosa-
mine induced hepatocellular carcinoma [22-24]. And
also expressions of several proapoptotic genes, such as
Fas, Puma and DR5 have been demonstrated to be upre-
gulated by NF-B [25-27]. Thus, we hypothesized that
NF-B might have the ability of regulating expression of
tumor suppressive miRNAs. Interestingly, bioinformatics
analysis revealed that there were several potential NF-
B binding sites located in the promoter region of miR-
34a gene. So, we wondered if miR-34a was a direct tar-
get of NF-B transcription factor. And this study was
aimed to investigate whether NF-B could directly regu-
late miR-34a expression and the way how they
regulated.
Results
NF-B activation correlates with miR-34a expression
In order to study whether NF-Bc o u l dr e g u l a t em i R -
34a expression, two different approaches were used to
alter NF-Bf u n c t i o ni nE C 1 0 9c e l l s ,a ne s o p h a g e a l
squamous cancer cell line containing wildtype p53
(data not shown). First, we enhanced the NF-Bp 6 5
levels by transfecting EC109 cells with a p65 expres-
sing vector, cells with overexpressed p65 exhibited an
increase of miR-34a levels compared with the vector
control cells (Figure 1a). Next, we blockaded the endo-
genous NF-B activity by transfecting EC109 cells with
dominant negative IBa which was refractory to phos-
phorylation mediated degradation. Transfection of this
mutant IBa indeed leaded a significant reduction of
nuclear NF-B p65 translocation. And the expression
of miR-34a was also sharply decreased in cells lacking
NF-B activity (Figure 1b). These results suggested
that NF-B activation was needed for miR-34a expres-
sion and activation of NF-B signal could upregulate
its expression levels.
Overexpression of NF-B p65 subunit enhances the
transcriptional activity of miR-34a
According to the bioinformatics analysis, three putative
NF-B binding sites were existed in miR-34a promoter
region, located upstream of the known p53 bind site (Fig-
ure 2a). To further study whether miR-34a was transcrip-
tionally regulated by NF-B, about 1.3 kb DNA fragment
containing the three putative NF-B binding sites and
the known p53 binding site was cloned into a promoter-
less luciferase reporter vecto r( P 1 ) .A l s ow ec o n s t r u c t e d
another four reporter vectors with different Bs i t e
mutated (M1, M2, M3) or p53 binding site mutated
(M53) (Figure 2b). Cotransfected p65 subunit with the
wildtype reporter vector into EC109 resulted in a mark-
able enhancement of luciferase activity compared with
the control. Mutation of the first NF-B binding site had
no impact on the transcriptional activity enhancement
caused by p65 overexpression, while mutation of the
other two greatly weakened the transactivity ability (Fig-
ure 2b). These indicated that these two sites had critical
roles in transcriptional regulation of miR-34a by NF-B.
Furthermore, we also found that mutation of the p53
binding site in miR-34a promoter region impaired the
transcriptional enhancement mediated by p65, suggesting
p53 may involve in NF-B mediate induction of miR-34a.
NF-B directly binds to the promoter region of miR-34a
gene
Since NF-B could regulate miR-34a expression at the
transcriptional level, we next investigated whether NF-
B could directly bind to the promoter region. EMSA
assay was first performed. Two oligonucleotides were
used in the experiment: 34a2KB probe containing the
second B site and 34a3ΚB containing the third B site.
34a3ΚB probes were detected bound with protein of
nuclear extract from EC109 cells, and supershift was
appeared in the presence of anti-p50 antibody (Figure
3a). No specific binding by nuclear extract protein was
observed with 34a2ΚB (data not shown). These results
suggested that regulatory region of miR-34a gene could
be bound with NF-B dimmers in EC109 cells.
Then we performed chromatin immunoprecipitation
analysis with EC109 cells to detect the binding of NF-
B in vivo. Three PCR amplicons were designed: one
flanking the first two B sites in miR-34a promoter
region (34aKB2), another flanking the third Bs i t e
(34aKB3) and the last one located in the intronic region
of miR-34a gene served as a control (34a intron). As
shown in Figure 3b, recruitment of p65 and p50 NF-B
subunit to the promoter region containing the third B
site was observed in EC109 cells. However, promoter
region flanking the first two B sites and the intronic
region had no obvious enrichment of these transcription
factors. Furthermore, binding of these transcription
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detected. As shown in Figure 3c, binding of NF-Bp 6 5
and p50 subunits to the promoter region containing the
third B site were boosted in cells with overexpressed
p65. No obvious enrichment in the first two Bs i t e s
was detected in transfected cells (data not shown).
Enhanced p53 binding to miR-34a promoter was
observed too. These results demonstrated that increased
binding of NF-B to miR-34a promoter was indeed
responsible for the induction in those transfected cells.
P53 is necessary for NF-B induced miR-34a transcription
but not for NF-B binding
For mutation of the known p53 binding site could
attenuate the effect of p65 on miR-34a transcriptional
activity, we speculated that p53 may coordinate with
NF-B to regulate miR-34a transcription. In order to
demonstrate this, KYSE450, another esophageal squa-
mous cancer cell line containing a mutant form of p53
(p53
H179R) was used in the following experiments. First,
we transfected KYSE450 cells with p65 expression vec-
tors, and ectopic p65 expression could not successfully
induced miR-34a expression (Figure 4a). When reintro-
ducing wildtype p53 into KYSE450 cells, miR-34a
induction by p65 overexpression was observed (Figure
4b). In addition, we decreased p53 protein levels in
EC109 cells using siRNA, and found that p65 was
unable to upregulate miR-34a expression then (Figure
4c). These findings gave us a hint that p53 was required
for NF-B-mediated miR-34a induction and promoted
us wondering how p53 affect this regulation.
We then performed luciferase reporter assay in
KYSE450 cells and EC109 cells with decreased p53
levels. Unlike the performance in normal EC109 cells,
cotransfection of p65 with miR-34a promoter reporter
vectors (P1) only cause a slight increase of the luciferase
activity in KYSE450 cells(Figure 5a). And knock-down
of p53 level dramatically impaired the transactivity
enhancement caused by p65 (Figure 5b). These indi-
cated that impairment or loss of wildtype p53 function
might affect NF-B p65-induced transactivity of miR-
34a. We next determined the binding of NF-B subunits
in KYSE450 cells. Surprisingly, nuclear extracts from
KYSE450 cells could still bound with 34a3KB probes
containing the third B site of miR-34a promoter (Fig-
ure 5c). CHIP assay performed with transfected
KYSE450 cells also showed an enhancement of NF-B
binding but not p53 binding (Figure 5d). These findings
Figure 1 NF-B activation correlates with miR-34a expression. (a) EC109 cells were transfected either with empty vector (pcDNA3.1) or p65
expression vector (p65), 48 h after transfection, changes of total p65, nuclear p65 and mature miR-34a levels were individually detected by
western blot or qRT-PCR. (b) EC109 cells were transfected either with empty vector (control) or with dominant negative mutant of IB (DN IB),
nuclear p65 and p50 protein levels and mature miR-34a levels were individually detected by western blot or qRT-PCR.
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seems not be affected by loss of wildtype p53 function.
The above results suggested NF-B could regulate
miR-34a expression. Since miR-34a is a known target of
p53, we wondered if miR-34a induction by p53 required
NF-B. EC109 cells were cotransfected with DNIB and
wildtype p53, however, miR-34a levels were still
increased by p53 overexpression in cells with decreased
NF-B activity (Figure 6). This suggested that NF-B
might not be necessary for p53-mediated miR-34a
induction.
Discussion
MiR-34a is an important tumor suppressive microRNA,
which dysregulated in many types of cancers. Delicated
study on its regulation mechanism is important for
exploring new strategies for cancer therapy. In this
study, we identified that:1) overexpression of NF-B p65
subunit could increase miR-34a levels and ectopic
expression of DN IB leaded a significant reduction of
miR-34a expression; 2) mutation of either the Bs i t e s
or the p53 binding site of miR-34a gene could impair
p65-induced transcriptional activity; 3) NF-Bc o u l d
specifically bind to the B site located at -149 of miR-
34a gene; 4) Expression of miR-34a could not be
induced by NF-B in the absence of wildtype p53 func-
tion, probably owing to the downregulated transcrip-
tional activity; 5) NF-B could bind with miR-34a
promoter even in cells with mutant p53; 6) NF-B
might not be necessary for p53-mediated miR-34a upre-
gulation. According to these findings, we concluded that
NF-B could directly activate miR-34a expression at the
transcriptional level and wildtype p53 might be respon-
sible for the transactivity but not for NF-B binding.
Previous studies have demonstrated that miR-34a is a
direct target of p53, our study revealed a novel mechan-
ism for miR-34a regulation. NF-B is an important tran-
script factor linking inflammation and immunity to
cancer initial and progression. It could be activated by a
variety of inflammatory cytokines existing in local envir-
onment of tumors [28]. Functioning as a downstream
target of NF-B, it is possible that miR-34a also involve
in inflammation-related tumorigenesis. Surprisingly, Elo-
die Roggli has recently reported that miR-34a is indeed
induced by two important inflammatory cytokines, IL-
1b and TNFa, in human islet cells [29]. Thus, our study
Figure 2 Overexpression of NF-B p65 subunit enhances the transcriptional activity of miR-34a. (a) Genomic structure for human miR-
34a gene. (b) EC109 cells were transfected with pCDNA3.1 or p65 in combination with the wildtype miR-34a promoter (P1) or promoter with
different NF-B binding site mutated (M1-M3) or promoter with p53 binding site mutated (M53). pRL-TK reporter plasmid was used as
transfection control. 48 h later, cells were lysised and luciferase assay were performed as described in Materials and Methods. Error bars represent
the standard deviations for three independent experiments. *P < 0.05 * * P < 0.01, t-test versus the P1 reporter vector control.
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miR-34a might play a role in tumor microenvironment
network through regulation by NFKB signal pathway.
However, the delicated function needs further
investigation.
Unlike many other transcription factors involved in
cancer biology, NF-B played a two-side role during the
process of carcinogenesis. Downstream genes responsible
for the tumor-promoting role of NF-B have been stu-
died exhaustively, such as antiapoptic gene, c-FLIP, Bcl-
XL and IAP family member [30-32]; cell cycle regulator,
cyclin D1 [33] and genes referring to environmental
modification, vascular endothelial growth factors (VEGF)
[34] and matrix metalloproteinases (MMPs)[35]. How-
ever, mechanism of tumor-suppressor role for NF-B
remains poorly understood. NF-kB had been reported to
induce G1 cell cycle arrest in human epithelial cells
through increasing of p21
cip or suppression of CDK4
[36,37]. Our work demonstrated miR-34a was a direct
target of NF-B. And miR-34a was verified to be able to
induce cell growth arrest or apoptosis by downregulating
expression of a variety of cell cycle regulator and antia-
poptotic genes, including CDK4 [2-11,38]. Thus, our
study also revealed a potential target for NF-B responsi-
ble to its inhibitory role in cancer progression.
In this study, we found that NF-B-mediated miR-34a
induction required wildtype p53 function. Actually, pre-
vious studies have also demonstrated p53 might play a
role in NF-B mediated gene expression. For example,
transcriptional activation of DR5 needed both NF-B
and p53 binding to the related sites and knock-down of
p53 expression blocked the binding of p65 with DR5
gene. [27]. And also NF-B has been reported to involve
in gene transcription regulated by p53. For example,
NF-B p52 subunit could modulate several p53 down-
stream genes transcription through binding to their pro-
moter region [39]. Our study revealed that NF-B-
mediated miR-34a transactivity might be affected by
p53, but binding of NF-Bt om i R - 3 4 ap r o m o t e rw a s
independent of p53. In addition, blocking nuclear trans-
location of NF-B p65/p50 dimmers seemed to have no
effect on p53-induced miR-34a expression.
Conclusions
Our study demonstrates a novel mechanism of miR-34a
regulation in human malignancies that NF-Bc o u l d
Figure 3 NF-B directly binds to the promoter region of miR-34a gene. (a) EMSA was performed with EC109 cells nuclear extracts using
probe corresponding to the third B site (34a3ΚB) in miR-34a promoter region. Competition and supershift assays against p53, p65 and p50
were also performed. (b) Chromatin derived from EC109 cells were immunoprecipitated with anti-p65, p50, p53 and IgG antibodies. Relative
enrichment of each transcription factor-bound DNA was detected by qPCR using primers described in the method. Shown were results
normalizing to input DNA. (c) CHIP assay were performed with EC109 cells transfected with p65 or control vectors, Relative enrichment of each
transcription factor-bound DNA was detected by qPCR using primer 34aΚB3.
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understanding the dysregulation of miR-34a in human
cancer tissues and opens new perspectives for the func-
tion of miR-34a and NF-B in tumor progression.
Methods
Plasmid construction
DNA sequence upstream of the human miR-34a gene
was amplified by PCR using the following primer sets:
34aF CTGCTCGAGTGCCGGTTCCTGGCTTTA, 34aR
GCGAAGCTTGCTGCAATATCACCGTG. PCR pro-
duct was cloned into pGL3-basic vector (Promega)
between the HindIII and XhoI sites. Site directed
mutagenesis was performed by overlap extension PCR
as described in [40]. And primers used were: 34aM53F
TGCCTGGGTTTACCTGGGTTTATTCCGAGCCG,
34aM53R CGGCTCGGAATAAACCCAGGTAAACC-
CAGGCA; 34aM1F GGCGACGAGTCGCCGGAAG-
GGTCGCGAT, 34aM1R TTCCGGCGACTCGTCGC-
CCCTTCGCGGT; 34a M2F ATGGCCCGGGAGT-
CGGGGACCTCGGCTC, 34aM2R AGGTCCCCGA-
CTCCCGGGCCATCGCGAC; 34a M3F TCGGTCT-
GGCGACAGCGCAGCTCCCCGGAT, 34a M3R AGC-
TGCGCTGTCGCCAGACCGACGGGAC. All the con-
structs were verified by sequencing.
Figure 4 P53 is required for NF-B-mediated miR-34a induction. (a)KYSE450 cells were transfected either with empty vector (pcDNA3.1) or
with p65 expression vector (p65), 48 h after transfection, levels of p65 and mature miR-34a were individually detected by western blot or qRT-
PCR. (b)KYSE450 cells were cotransfected with wildtype p53 or control vectors and p65 expression vectors or pCDNA3.1, 48 h after transfection,
levels of p53 and mature miR-34a were individually detected by western blot or qRT-PCR. (c) pCDNA3.1or p65 and siRNA control or sip53 were
cotransfected into EC109 cells. P53 protein and mature miR-34a levels were individually detected by western blot or qRT-PCR 48 h after
transfection.
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kindly provided by Dr M. Cippitelli (University of Rome
Sapienza, Rome, Italy) and Dr D. Fruci (Research Cen-
ter, Ospedale Bambino Gesù, Rome, Italy). Wildtype p53
expression vector was a gift from Prof. Dong Wang
(Third Military Medical University, Chongqing, China).
Cell culture and transfection
Human esophageal cancer cell line EC109 were pur-
chased from Cell Bank of Chinese Academy of Sciences,
Shanghai, China. KYSE450 were obtained from Cancer
Institute, Chinese Academy of Medical Sciences, Beijing,
China. All cells were cultured in 1640 supplemented
with 10% FBS, at 37°C in a humidified incubator con-
taining 5% CO2.
For gene expression transfection, plasmids were trans-
fected with lipofectamine2000 (Invitrogen) according to
the manufacturer’s instructions. Gene expression levels
were detected 48 h after transfection.
RNA extraction and Real-Time qRT-PCR
Total RNA was extracted using RNAiso reagent
(Takara) according to the manufacturer’s instructions
and quantified with a NanoDrop spectrophotometer
(Thermo Scientific). MiR-34a expression was measured
using a TaqMan MicroRNA RT-PCR assay (Applied
Biosystems). 100 ng total RNA was converted to cDNA
using specific primers, and amplification of the cDNA
was done using Taqman Universal PCR Master Mix
(Applied Biosystems). PCR conditions were 95°C for 3
Figure 5 P53 is necessary for NF-B-induced miR-34a transcriptional activity but not for NF-Bb i n d i n g .( a )K Y S E 4 5 0c e l l sw e r e
transfected with pCDNA3.1or p65 in combination with the wildtype miR-34a promoter (P1). pRL-TK was used as transfection control. Cells were
lysised and luciferase assay were performed 48 h after transfection. Error bars represent the standard deviations for three independent
experiments. (b) pCDNA3.1or p65 and siRNA control or sip53 along with the wildtype miR-34a promoter were cotransfected in EC109. pRL-TK
vectors were used as transfection control. Luciferase assay were performed 48 h after transfection. Error bars represent the standard deviations
for three independent experiments. (c) EMSA was performed with nuclear extracts from KYSE450 cells using probe corresponding to the third B
site (34a3ΚB) in miR-34a promoter region. Competition and supershift assays against anti-p53, p65 and p50 antibody were also shown. (d)
Chromatin derived from KYSE450 cells transfected with p65 or control vectors were immunoprecipitated with anti-p65, p50, p53 and IgG
antibodies. Relative enrichment of each transcription factor-bound DNA was detected by qPCR using 34aΚB3 primers. Shown were results
normalizing to input DNA.
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60°C for 40 seconds. The expression of MiR-34a was
normalized against U6 snRNA expression.
Western blot
For total protein analysis, cells were harvested and
lysised in T-PER Tissue Protein Extraction Reagent
(Pierce Chemical Company) with freshly added PMSF.
For nuclear protein analysis, cells were lysised with
Nuclear and Cytoplasmic Protein Extraction Kit (beyo-
time). Proteins were separated by SDS-PAGE and elec-
trotransferred to PVDF membranes, after blocked with
5% skimmed milk, membranes were incubated with a
primary antibody and then incubated with a horseradish
peroxidase-conjugated secondary antibody. Antibodies
used were anti- NF-B p65 (sc-372, Santa Cruz Biotech-
nology), anti- NF-B p50 (06-886, upstate), anti-p53 (sc-
126x, Santa Cruz Biotechnology), anti-lamin B1 (SC-
56145, Santa Cruz Biotechnology), HRP-conjugated
monoclonal mouse anti-glyceraldehyde-3-phosphate
Dehydrogease (KC5G5, Kangchen Bio-Tech) and horse-
radish-peroxidase coupled goat antibodies against rabbit
and mouse immunoglobulins (Beijing Zhongshan
Golden Bridge Biotechnology). The immunoreactive
proteins were detected using SuperSignal West Dura
Extended Duration Substrate (Thermo Scientific).
Reporter assay
For reporter assay, p65 expression vectors or the control
vectors were cotransfected with pGL3 reporter vectors
along with pRL-TK vector (Renilla luciferase, Promega)
using lipofectamine2000. Cell lysate was collected 48 h
after transfection and luciferase activities were measured
using Dual-Luciferase Reporter Assay System (promega).
Activity was defined as Firefly/Renilla ratio and normal-
ized to the negative control vector transfection.
Figure 6 Blocking of NF-B activation might not affect miR-34a induction by p53. EC109 cells were cotransfected by wildtype p53 or
control vectors and DNIB or control, p53 protein and mature miR-34a levels were individually detected by western blot or qRT-PCR 48 h after
transfection.
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ChIP was performed with a commercially available
Chromatin Immuno-precipitation Kit (Upstate Biotech-
nology) according to the manufacturer’si n s t r u c t i o n s .
Briefly, cells (2 × 106/immunoprecipitation) were cross-
linked in 1% formaldehyde for 10 min at room tempera-
ture and halted the cross-link with 0.125M glycine.
Chromatin was captured with the following primary
a n t i b o d y :p 6 5( c e l ls i g n a lt e c h n o l o g y ,3 9 8 7 ) ,p 5 0
(upstate, 06-886), p53 (santa sc-126x), IgG (millipore,
12-371B). After overnight capture at 4°C, chromatin was
collected, purified and then decrosslinked at 65°C. DNA
was recovered using Spin Columns and the enrichment
was detected by qPCR. Following primers were used in
PCR assay: 34aΚB2, F CCCCCGTGGTTTCTGTTTG, R
CCTGGGCTGGCGTTTC; 34aΚB3, F TGCGTGGT-
CACCGAGAAGCAG, R TTCAGGTGGAGGAGATG-
CCGC; 34a intron, F GCTCCATCCTCGGACCTGA, R
GGCGGTCTGAGTTGGCTAG.
Electrophoretic mobility shift assays
EMSA was performed according to the manufacturer’s
instruction of (Pierce). Nuclear protein of EC109 and
KYSE450 cells were extracted using the Nuclear and
Cytoplasmic Protein Extraction Kit (beyotime). In brief,
biotin labelled DNA probes containing candidate NF-B
binding sites from miR-34a promoter (34aΚB2
TCGCGATGGCCGGGGAGTCCGGGACCTCGGCT,
34aΚB3 CCGTCGGTCTGGGGACAGCCCAGCTCC-
CCGGA, only one stand shown) were mixed with 10 ug
of nuclear extract in a 20 ul reaction volume containing
1X binding buffer, 5 mM MgCl2, 5% glycerol, 0.05%
NP40 and 50 ng/ul poly(dI:dC). The reaction mixture
was incubated on ice for 30 min and applied to a 6%
nondenatured polyacrylamide gel containing 0.5X TBE
buffer. For competition assays, a 200-fold molar excess
of unlabeled probes and unlabeled mutated probes
(34aΚB2M TCGCGATGGCCCGGGAGTCGGGGAC-
CTCGGCT, 34aΚB3M CCGTCGGTCTGGCGACAG-
CGCAGCTCCCCGGA) were added prior to the
labelled probe. For supershift assays, antibodies against
p65, p50 and p53 were added in the binding reaction
after DNA-protein incubation. After electrophoresis,
DNA-protein complex was transferred to a nylon mem-
brane, and cross-linked. Then the biotinylated-labelled
DNA detected by chemiluminescence according to the
manufacturer’s directions.
Statistics
Statistical analyses were performed with SPSS 16.0
(SPSS Inc., Chicago, IL, USA). Differences between
experimental groups and control groups were assessed
by Student’s t-test. P < 0.05 was considered to be statis-
tically significant.
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